GS
AUPH icon

GTS Securities’s Aurinia Pharmaceuticals AUPH Stock Holding History

GTS Securities’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-106,500
Closed -$781K – 1461
2024
Q3 		$781K Buy
106,500
+10,800
+11% +$67K ﹤0.01% 2393
2024
Q2 		$546K Sell
95,700
-151,500
-61% -$798K ﹤0.01% 2622
2024
Q1 		$1.24M Buy
247,200
+220,000
+809% +$1.49M ﹤0.01% 1833
2023
Q4 		$245K Buy
27,200
+9,300
+52% +$76.6K ﹤0.01% 3394
2023
Q3 		$139K Buy
+17,900
New +$175K ﹤0.01% 3529

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

GTS Securities's AUPH Position: Q4 2024 in Review

GTS Securities sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2024, closing a stake of 53,327 shares — an estimated $391K sold.

GTS Securities first reported a position in AUPH in Q4 2023 and held it in 4 quarters. The position peaked at $628K in Q1 2024. 200 funds tracked by Wall St. Rank hold AUPH as of Q4 2024.

  • GTS Securities reported no remaining Aurinia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 53,327 Aurinia Pharmaceuticals shares in Q4 2024, an estimated $391K.
  • GTS Securities first reported a position in Aurinia Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • GTS Securities's Aurinia Pharmaceuticals position peaked at $628K in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.